ControversiesChallengesConsensus

New APERTO AVF RCT data show DCB reduces restenosis significantly more than high-pressure balloon alone

2019-04-24T13:56:58+01:00

Matteo Tozzi (Varese, Italy) discusses new data from the APERTO AVF study, the first randomised trial in China to compare the safety and efficacy of the APERTO drug-coated balloon (DCB; Cardionovum) with a high-pressure balloon. The trial results for the treatment of failing haemodialysis arteriovenous shunts were presented by Qizhuang […]

New APERTO AVF RCT data show DCB reduces restenosis significantly more than high-pressure balloon alone2019-04-24T13:56:58+01:00

TEVAR performed outside the IFU has “dramatically worse outcomes”

2019-04-18T17:33:06+01:00

Dittmar Boeckler (Heidelberg, Germany) tells CX Live that treating patients with thoracic endovascular aortic repair (TEVAR) outside the instructions for use (IFU) has a dramatic effect on patient outcomes after the procedure. “We observed a significant increase in mortality […] an increased reintervention rate and four times higher endoleak rate,” […]

TEVAR performed outside the IFU has “dramatically worse outcomes”2019-04-18T17:33:06+01:00

CX 2019: Highlights from the inaugural iWounds Workshop

2019-04-18T17:14:49+01:00

Michael Edmonds (London, UK), Tomas Serena (Warren, USA), Keith Harding (Cardiff, UK), and Williams Ennis (Oak Lawn, USA) talk at CX Live about the first ever iWounds workshop, the importance of wound management and what they hope to achieve.

Edmonds discusses why “too many legs are being lost” and Serena talks […]

CX 2019: Highlights from the inaugural iWounds Workshop2019-04-18T17:14:49+01:00

Hear the latest thoughts on paclitaxel from global experts: their current practice and patient conversations

2019-04-18T15:33:23+01:00

Following the latest information presented at the Charing Cross International Symposium related to the meta-analysis of paclitaxel-coated devices (Katsanos et al, JAHA), hear from a multi-specialty panel of global experts who are discussing their current practice and the way they […]

Hear the latest thoughts on paclitaxel from global experts: their current practice and patient conversations2019-04-18T15:33:23+01:00

Don’t miss: The influence of hyperglycaemia on spinal cord injury

2019-04-18T11:39:14+01:00

Jade Hiramoto (San Francisco, USA) tells CX Live about why she believes “everyone should consider normalising glucose levels after long, complex endovascular aortic procedures—and maybe even after open thoracoabdominal aortic procedures.”

Hiramoto is presenting new research on this topic at the Charing Cross session on Spinal Cord Ischaemia in the Upper […]

Don’t miss: The influence of hyperglycaemia on spinal cord injury2019-04-18T11:39:14+01:00

CX 2019: Why a signed consent form “is not consent”

2019-04-17T20:34:29+01:00

Jonathan Beard, (Sheffield, UK), discusses the current medicolegal issues in the field and explains how vascular surgeons can become “the fall-guy for the inadequacies of other clinicians”. Beard touches on how the threshold for informed consent has changed “dramatically” in recent years which has led to “the death of […]

CX 2019: Why a signed consent form “is not consent”2019-04-17T20:34:29+01:00

News from CX 2019: Evidence supports safety of paclitaxel-coated devices

2019-04-17T15:40:40+01:00

At the Charing Cross International Symposium, Gary Ansel (Columbus, Ohio) moderates a global panel that includes Thomas Albrecht (Berlin, Germany), Peter Schneider (San Francisco, USA) and Eric Secemsky (Boston, USA). The panel outlines the value of paclitaxel devices in the treatment of peripheral arterial disease patients; examines new evidence on […]

News from CX 2019: Evidence supports safety of paclitaxel-coated devices2019-04-17T15:40:40+01:00

Breaking news from CX 2019: Cook leads the way to data transparency with release of long-term ZILVER PTX patient-level data

2019-04-17T11:51:20+01:00

There were several calls at the CX 2019 Highlight Session Paclitaxel: The last word on the need for a meta-analysis of individual patient-level data going forward and greater transparency and sharing of the available randomised controlled trial data of paclitaxel-coated devices.

Cook Medical has just announced the release of de-identifiable […]

Breaking news from CX 2019: Cook leads the way to data transparency with release of long-term ZILVER PTX patient-level data2019-04-17T11:51:20+01:00

Key take-aways from the CX 2019 Highlight Session on Paclitaxel: The Last Word

2019-04-17T09:48:40+01:00

Elena Ladich (Hollywood, USA) and Roger Greenhalgh (London, UK) discuss the current uncertainty surrounding the use of paclitaxel devices and the need for individual patient-level data analyses going forward to better understand the mortality signal raised by the Katsanos et al meta-analysis.

Ladich believes that “we need to take a step […]

Key take-aways from the CX 2019 Highlight Session on Paclitaxel: The Last Word2019-04-17T09:48:40+01:00

CX 2019: Stroke following cardiac surgery is a “wake-up call”; safety of carotid stenting debate

2019-04-16T17:04:52+01:00

In the Acute Stroke Challenges session on Monday, Nick Hopkins talks to CX Live about the “significant increase” of incidents of stroke following cardiac surgery which is “much more common than previously thought”.

Ross Naylor and Peter Schneider debated the impact of new technologies and innovations […]

CX 2019: Stroke following cardiac surgery is a “wake-up call”; safety of carotid stenting debate2019-04-16T17:04:52+01:00

CX Special Session will discuss the use of paclitaxel devices

2019-03-11T16:07:49+01:00

CX Executive Board Members Gunnar Tepe and Thomas Zeller introduce the CX Special Session which aims to give the last word on paclitaxel and work with the vascular community to find the way forward.

Watch the video below, and see the final CX 2019 programme here.

[…]

CX Special Session will discuss the use of paclitaxel devices2019-03-11T16:07:49+01:00

CX 2019: NICE AAA guidelines under the spotlight

2019-02-18T10:22:42+01:00


The publication of the draft aortic guidelines by the National Institute for Health and Care Excellence (NICE) in May 2018 raised quite a stir.

However, the story is not over. In a CX Special Session, new analysis will show what we now know about long-term EVAR outcomes, and the vascular community’s concerns over the […]

CX 2019: NICE AAA guidelines under the spotlight2019-02-18T10:22:42+01:00

CX 2019: Vascular EDUCATION as it should be

2019-04-12T13:44:22+01:00

CX is Europe’s largest and longest-running vascular symposium and delivers vascular EDUCATION as it should be

CX raises CONTROVERSIESCHALLENGES the evidence to reach CONSENSUS in a three yearly cycle after discussion involving a world-class faculty and expert audience.

CX uses both live cases and edited cases from leading aortic, peripheral and venous centres to illustrate […]

CX 2019: Vascular EDUCATION as it should be2019-04-12T13:44:22+01:00

CX 2019: The last word on the paclitaxel controversy

2019-02-07T17:15:34+01:00

Since the publication of Katsanos et al’s meta-analysis in the Journal of the American Heart Association (JAHA), the science and support for paclitaxel-releasing devices in the legs is an unfolding story.

A CX 2019 Highlight session will feature two hours of independent review of the data and in-depth debate and discussion.

CX […]

CX 2019: The last word on the paclitaxel controversy2019-02-07T17:15:34+01:00

CX 2019: Stephen Black on the Venous Challenges programme

2019-01-04T15:01:38+01:00

Stephen Black, member of the CX Venous Executive Board, describes the wonderful opportunity that the Charing Cross Venous Challenges Programme offers as it brings together key developments in the science, learning experience in the Venous Village and input from the international faculty who share their vision.

 

CX 2019: Stephen Black on the Venous Challenges programme2019-01-04T15:01:38+01:00

CX 2019 Peripheral Challenges Programme Highlights

2019-01-04T15:02:26+01:00

From new outcomes of paclitaxel-coated devices to DCB use below the knee, the CX Peripheral Executive Board looks ahead to CX 2019 and raises some of the key questions that will be addressed in the programme.

CX 2019 Peripheral Challenges Programme Highlights2019-01-04T15:02:26+01:00

CX Symposium provides “ideal opportunity” to share your research

2018-08-16T16:44:15+01:00

In this interview, Meryl Davis, chair of the CX Abstract Board, talks about the benefits of presenting research at the CX Symposium and the importance of CX as a “global village”.

The CX Abstract Board is calling for senior and trainee doctors in the vascular and endovascular field to submit their […]

CX Symposium provides “ideal opportunity” to share your research2018-08-16T16:44:15+01:00

EVRA (Early Venous Reflux Ablation) Ulcer Trial presented for the first time at the Charing Cross Symposium

2018-04-24T15:50:47+01:00

Alun Davies, EVRA chief investigator
Imperial College, London, United Kingdom

EVRA (Early Venous Reflux Ablation) Ulcer Trial presented for the first time at the Charing Cross Symposium2018-04-24T15:50:47+01:00

CX 2018: 40 Years of Looking Forward with vascular education as it should be!

2018-03-23T18:01:07+01:00

This year, CX celebrates 40 Years of Looking Forward. In this video, members of the CX Programme Organising Board and the CX Faculty explain why CX is not only unique but also provides vascular education “as it should be”! Register now for CX 2018!

CX 2018: 40 Years of Looking Forward with vascular education as it should be!2018-03-23T18:01:07+01:00

The opportunity for discussion is a key benefit of CX

2018-02-15T14:35:40+01:00

Fabrizio Fanelli (Florence, Italy), CX Faculty, says that a key point about CX is that it – unlike other meetings – provides opportunities for discussion. He notes that the “active discussion” at the podium is “very important” for what you learn at the meeting. Register for CX 2018!

[…]

The opportunity for discussion is a key benefit of CX2018-02-15T14:35:40+01:00

CX has had “a very significant impact on my practice”

2018-04-05T17:53:26+01:00

CX Faculty member Barry Katzen (Miami, United States) discusses how attending CX has affected his clinical practice and how he always is “universally losing” debates at CX! Register for CX 2018! 

CX has had “a very significant impact on my practice”2018-04-05T17:53:26+01:00

“Excellent” is the word Prof Davies uses to describe CX

2018-02-15T14:27:22+01:00

CX programme organising board member Alun Davies (Imperial College, London, United Kingdom) reviews how CX has changed in the last 24 years that he has been attending the symposium, his most memorable moments, and the one word he would use to describe the meeting. Register for CX 2018!

[…]

“Excellent” is the word Prof Davies uses to describe CX2018-02-15T14:27:22+01:00

“Every time I come to CX, I learn more and more”

2018-02-15T14:20:26+01:00

“One of the great things” about CX, according to CX Faculty member Kathleen Gibson (Bellevue, United States), is that it provides a “global perspective”. She says she “learns more and more” every time she attends. Register for CX 2018!

“Every time I come to CX, I learn more and more”2018-02-15T14:20:26+01:00